[go: up one dir, main page]

NO20084441L - Triazolonderivat - Google Patents

Triazolonderivat Download PDF

Info

Publication number
NO20084441L
NO20084441L NO20084441A NO20084441A NO20084441L NO 20084441 L NO20084441 L NO 20084441L NO 20084441 A NO20084441 A NO 20084441A NO 20084441 A NO20084441 A NO 20084441A NO 20084441 L NO20084441 L NO 20084441L
Authority
NO
Norway
Prior art keywords
optionally substituted
independently represent
represent hydrogen
represents optionally
independently
Prior art date
Application number
NO20084441A
Other languages
English (en)
Inventor
Shinsuke Hirota
Kazutomi Kusano
Richard Clark
Fumiyoshi Matsuura
Kazunobu Kira
Hiroshi Azuma
Tadashi Nagakura
Tatsuo Horizoe
Kimiyo Tabata
Takao Omae
Atsushi Inoue
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of NO20084441L publication Critical patent/NO20084441L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Forbindelser med den generelle formel (1), salter derav og deres hydrater (1) I formelen er hver av R1a, R1b, R1c og R1d uavhengig et hydrogenatom, etc. R2 er et eventuelt substituert fenyl, etc. R3 er et eventuelt substituert C6-10 aryl, etc. Hver av Z1 og Z2 er uavhengig et hydrogenatom. Disse er anvendbare som et terapeutisk middel og/eller forebyggende middel for sykdommer forårsaket av levringsdannelse, er sikrere, og har passende fysiokjemisk stabilitet.

Claims (1)

  1. Forbindelser med den generelle formel (1), salter derav og deres hydrater I formelen er hver av Rla, Rlb, RlQ og Rld uavhengig et hydrogenatom, etc. R <2> er et eventuelt substituert fenyl, etc. R <3> er et eventuelt substituert C6-10 aryl,
    etc. Hver av Z <1> og Z <2> er uavhengig et hydrogenatom.
    Disse er anvendbare som et terapeutisk middel og/eller forebyggende middel for sykdommer forårsaket av levringsdannelse, er sikrere, og har passende fysiokjemisk stabilitet.
NO20084441A 2006-03-24 2008-10-22 Triazolonderivat NO20084441L (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2006083486 2006-03-24
US78668706P 2006-03-29 2006-03-29
JP2006162594 2006-06-12
US80487806P 2006-06-15 2006-06-15
JP2006218819 2006-08-10
US83841806P 2006-08-18 2006-08-18
PCT/JP2007/055813 WO2007111212A1 (ja) 2006-03-24 2007-03-22 トリアゾロン誘導体

Publications (1)

Publication Number Publication Date
NO20084441L true NO20084441L (no) 2008-12-22

Family

ID=38950011

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084441A NO20084441L (no) 2006-03-24 2008-10-22 Triazolonderivat

Country Status (25)

Country Link
US (3) US7816522B2 (no)
EP (2) EP2194046B1 (no)
JP (1) JP5016592B2 (no)
KR (1) KR101362024B1 (no)
AT (2) ATE491694T1 (no)
AU (1) AU2007230346B2 (no)
BR (1) BRPI0709101A2 (no)
CA (1) CA2647423C (no)
CY (1) CY1111271T1 (no)
DE (1) DE602007011231D1 (no)
DK (1) DK2000465T3 (no)
HR (1) HRP20110054T1 (no)
IL (1) IL194188A (no)
MX (1) MX2008012031A (no)
MY (1) MY146537A (no)
NO (1) NO20084441L (no)
NZ (1) NZ571441A (no)
PL (1) PL2000465T3 (no)
PT (1) PT2000465E (no)
RS (1) RS52030B (no)
SA (1) SA07280131B1 (no)
SI (1) SI2000465T1 (no)
TW (1) TWI389894B (no)
WO (1) WO2007111212A1 (no)
ZA (1) ZA200805758B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4478157B2 (ja) * 2004-10-13 2010-06-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヒドラジド誘導体
KR101362024B1 (ko) 2006-03-24 2014-02-11 에자이 알앤드디 매니지먼트 가부시키가이샤 트리아졸론 유도체
US7807690B2 (en) * 2007-09-21 2010-10-05 Eisai R&D Management Co., Ltd. 2,3-dihydro-iminoisoindole derivatives
WO2009054791A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
CN101918399A (zh) * 2007-10-26 2010-12-15 阿斯利康(瑞典)有限公司 作为mglur5调节剂的氨基1,2,4-三唑衍生物
TW201206905A (en) * 2010-05-20 2012-02-16 Eisai R & Amp D Man Co Ltd Prodrug of triazolone compound
WO2013134562A1 (en) * 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
CN102993109A (zh) * 2012-12-03 2013-03-27 浙江工业大学 一种脒化合物的制备方法
US9676754B2 (en) 2012-12-20 2017-06-13 Inception 2, Inc. Triazolone compounds and uses thereof
PE20160880A1 (es) 2013-09-06 2016-09-22 Inception 2 Inc Compuestos de triazolona y usos de los mismos
EP3588064B1 (en) * 2017-02-23 2022-09-07 IHI Corporation Oh radical detection probe, oh radical measurement device, and oh radical measurement method

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2005000A (en) * 1931-07-18 1935-06-18 L N Miller Engineering Corp Differential motor
EP0019586A1 (de) 1979-05-11 1980-11-26 Ciba-Geigy Ag Neue antithrombotische Kombinationspräparate
SU1512055A1 (ru) 1987-12-04 1992-07-23 Пермский фармацевтический институт Дигидрохлорид гидразида N-ацетил-N-аллилантраниловой кислоты, про вл ющий антиагрегатную активность по отношению к тромбоцитам плазмы крови
CN1268116A (zh) 1997-08-27 2000-09-27 橘生药品工业株式会社 3－脒基苯胺衍生物,活化血凝固因子x抑制剂和制备这些物质的中间体
AU2300699A (en) 1998-02-17 1999-08-30 Ono Pharmaceutical Co. Ltd. Amidino derivatives and drugs containing the same as the active ingredient
DE69920888T2 (de) * 1998-03-27 2006-02-02 Bristol-Myers Squibb Pharma Co. Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren
DE69919743T2 (de) 1998-12-14 2005-09-01 F. Hoffmann-La Roche Ag Phenylglycin-derivate
PL350042A1 (en) * 1999-01-13 2002-10-21 Genentech Inc Serine protease inhibitors
FR2791683A1 (fr) 1999-03-30 2000-10-06 Synthelabo Derives de n-sulfonyl-dipeptides, leur preparation et leur application en therapeutique
FR2793247B1 (fr) 1999-05-04 2001-06-22 Synthelabo Derives de 6-[[(aryl et heteroaryl)oxy]methyl]naphtalene-2- carboximidamide, leur preparation et leur application en therapeutique
US6548694B2 (en) 2000-05-23 2003-04-15 Hoffman-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
DE60233043D1 (de) 2001-04-19 2009-09-03 Eisai R&D Man Co Ltd 2-iminoimidazolderivate
JP4209659B2 (ja) 2001-11-15 2009-01-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 アミジノ誘導体並びにそれを用いた抗血液凝固剤および血栓症治療剤
EP1312602A1 (en) 2001-11-15 2003-05-21 Eisai Co., Ltd. Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them
EP1558581A4 (en) * 2002-10-07 2007-07-25 Bristol Myers Squibb Co DERIVATIVES OF TRIAZOLONE AND TRIAZOLETHIONE
EP1479679A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Triazole-derivatives as factor Xa inhibitors
JP4478157B2 (ja) 2004-10-13 2010-06-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヒドラジド誘導体
EP1828152B1 (en) 2004-12-08 2008-08-20 Bristol-Myers Squibb Company Heterocyclic compounds as inhibitors of factor viia
KR101362024B1 (ko) 2006-03-24 2014-02-11 에자이 알앤드디 매니지먼트 가부시키가이샤 트리아졸론 유도체
US7807690B2 (en) 2007-09-21 2010-10-05 Eisai R&D Management Co., Ltd. 2,3-dihydro-iminoisoindole derivatives

Also Published As

Publication number Publication date
KR101362024B1 (ko) 2014-02-11
US20110112109A1 (en) 2011-05-12
CA2647423A1 (en) 2007-10-04
CY1111271T1 (el) 2015-08-05
EP2000465A4 (en) 2009-08-26
HK1123808A1 (en) 2009-06-26
TWI389894B (zh) 2013-03-21
PT2000465E (pt) 2011-02-10
EP2194046A1 (en) 2010-06-09
HRP20110054T1 (hr) 2011-02-28
ATE491694T1 (de) 2011-01-15
US7816522B2 (en) 2010-10-19
WO2007111212A1 (ja) 2007-10-04
US20080015199A1 (en) 2008-01-17
DK2000465T3 (da) 2011-02-07
CA2647423C (en) 2015-02-17
ZA200805758B (en) 2009-12-30
US8163787B2 (en) 2012-04-24
MX2008012031A (es) 2008-10-02
EP2000465B1 (en) 2010-12-15
NZ571441A (en) 2010-08-27
DE602007011231D1 (de) 2011-01-27
MY146537A (en) 2012-08-15
EP2194046B1 (en) 2012-05-09
BRPI0709101A2 (pt) 2011-06-28
US7928228B2 (en) 2011-04-19
JPWO2007111212A1 (ja) 2009-08-13
ATE557010T1 (de) 2012-05-15
JP5016592B2 (ja) 2012-09-05
IL194188A (en) 2013-08-29
SA07280131B1 (ar) 2010-03-08
AU2007230346B2 (en) 2011-12-22
SI2000465T1 (sl) 2011-04-29
PL2000465T3 (pl) 2011-05-31
EP2000465A1 (en) 2008-12-10
US20100190783A1 (en) 2010-07-29
AU2007230346A1 (en) 2007-10-04
RS52030B (sr) 2012-04-30
TW200745063A (en) 2007-12-16
KR20090014341A (ko) 2009-02-10

Similar Documents

Publication Publication Date Title
NO20084441L (no) Triazolonderivat
NO20073416L (no) Indoler nyttig i behandlingen av inflammasjon
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
EP1953154A4 (en) CINNAMIDE COMPOUNDS OF MORPHOLINE TYPE
NO20062370L (no) Amidderivater
PT2415771E (pt) Derivado de indolizina e sua utilização para fins médicos
NO20053748L (no) Pyrrolopyridazinderivater.
NO20064599L (no) Substituerte morfolin- og tiomorfolinderivater
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
NO20055632L (no) Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater
EP2261224A3 (en) 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors
NO20071319L (no) Fremgangsmate for fremstilling av isotiazolderivater.
NO20051011L (no) Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister
WO2009038157A1 (ja) ２，３－ジヒドロ－イミノイソインドール誘導体
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
NO20060718L (no) Substituerte tiofoner og deres anvendelse
IL187917A (en) Compounds 1– (Converted phenyl) -pyreno [3,4– b] [1] benzofuran-3-van
EP2045258A4 (en) 3y-ETHYNYLCYTIDINDERIVAT
NO20054418L (no) Substituert benzoylureidopyridylpiperidin- og -pyrrolidinkarboksylsyrederivater, deres fremstilling og anvendelse
WO2007054484A8 (en) Process for the preparation of betamimetic benzoxazinone derivatives
DE60203106D1 (de) Azolylcarbynol-derivative von aryl (oder heteroaryl) zur behandlung von atemwegserkrankungen
DK1589023T3 (da) Oligosaccharid-derivat
DE60219619D1 (de) Mittel zur behandlung von myelopathie
MX2008002753A (es) Derivados de piridazinona utilizados para el tratamiento de dolor.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application